Becton, Dickinson and Company (BDX) , popularly known as BD, is well-poised for growth in the coming quarters, courtesy of its solid product portfolio. The optimism led by a solid second-quarter fiscal 2024 performance and a few strategic deals are expected to contribute further. However, macroeconomic concerns and stiff competition persist. Over the past year, this Zacks Rank #3 (Hold) stock has lost 5.2% against the 4% rise of the industry and 23.3% growth of the S&P 500. The renowned medical technology c ...

Combination unlocks new future value-creation opportunities and is expected to be immediately accretive to BD revenue growth, adjusted gross margin, adjusted operating margin and adjusted EPS Expands BD's portfolio of smart connected care solutions with complementary and broad set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline Critical Care to operate as a separate business unit within BD's Medical segment, based in Irvine, Calif. and led by Ka ...

champpixs 2024 Review The optimistic run for the stock market halts in April as the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) slides 4.69%, posting its worst monthly loss since September 2023. Much of this loss was recovered in early May; however, the latter part of the month has not been kind to most dividend aristocrats. Through May 28th (mid-day) NOBL is up only 0.53%. Despite the setback in April, NOBL remains positive year-to-date, +2.46% (1/1/24 - 5/28/24). Several dividend aristocrats are run ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently received the FDA’s approval for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing when cervical specimens cannot otherwise be obtained. The approval is expected to enable women to self-collect vaginal specimens for HPV testing in a healthcare setting, including non-traditional locations such as retail pharmacies or mobile clinics. Per estimates, HPV is the cause of virtually all cervical cancer and HPV tes ...

FRANKLIN LAKES, N.J., May 15, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) approval for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing when cervical specimens cannot otherwise be obtained. The approval allows women to self-collect vaginal specimens for HPV testing in a health care setting, which could include non-traditional locations such as a reta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-4802 Becton, Dickinson and Company (Exact name of registrant as specified in its charter) New Jersey 22-0760120 (State or other ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium includes access to the Zacks Style Scores as ...

财务数据和关键指标变化 - 第二财季收入为50亿美元,有机增长5.7%,主要由于输注系统强劲表现带动 [20][21] - 调整后毛利率为53%,调整后营业利润率为24.3%,均超预期,主要得益于简化举措和BD卓越运营系统的推进 [23] - 第二财季调整后每股收益为3.17美元,同比增长10.8% [23] - 前两个季度自由现金流超过11亿美元,同比增长超过9亿美元,有望实现第二年双位数自由现金流增长 [24][25] 各条业务线数据和关键指标变化 - BD医疗业务增长由输注系统带动,输注系统收入强劲增长,药物递送解决方案在美国和欧洲中欧中单位数增长 [21] - BD生命科学业务增长由诊断解决方案带动,微生物检测平台高单位数增长,标本管理中单位数增长 [21] - BD介入业务增长由持续强劲的尿失禁护理和外科手术业务带动,外科手术业务全球采用可吸收支架产品Phasix带动双位数增长 [22] 各个市场数据和关键指标变化 - 美国市场是增长的主要驱动力,中国市场受预期市场动态影响有所下滑 [20] 公司战略和发展方向及行业竞争 - 公司继续执行BD 2025战略,推进创新管线,包括连接式药物管理解决方案、外周血管疾病平台等,为公司5.5%以上的目标增长奠定基础 [10][13][14] - 公司正在推进Alaris泵的再次上市,第二财季创下生产和出货的历史新高,客户反馈积极,合同签订势头良好,为下半年增长做好准备 [11][12] - 公司正计划在今年晚些时候提交Alaris的下一个510(k)申请,进一步增强功能,如无线软件升级和网络安全等 [12] - 公司正在推进Pyxis药品分发平台的新一代产品,提升云连接性和分析能力 [13] - 公司正在整合医疗数据,将急性护理的Pyxis数据与非急性护理的MedBank和MedKeeper数据连接,为客户提供全程药品流向可见性 [13] 管理层对经营环境和未来前景的评论 - 公司对第二财季的强劲增长和超预期的利润表现感到满意,有信心实现2024财年的收入和利润目标 [9][18] - 公司对Alaris的再次上市和产能扩张感到自信,预计2024财年Alaris收入至少3亿美元,为2025财年的400万美元历史水平做好准备 [11][59][60] - 公司对BD卓越运营系统的推进和成本改善措施感到乐观,有信心实现2025财年25%的营业利润率目标 [15][68] - 公司对生命科学研究和制药系统业务的短期波动保持警惕,但相信随着市场环境改善,这些业务长期前景良好 [49][50] 问答环节重要的提问和回答 问题1 **Travis Steed 提问** 询问第二半年收入和利润率的具体驱动因素 [37] **Chris DelOrefice 回答** - Alaris将贡献近250个基点的收入增长,剩余业务有望实现5%以上的增长 [38][39][40] - 毛利率提升得益于成本改善举措和BD卓越运营系统的推进,以及去年一次性因素的消除 [42][43] 问题2 **Robbie Marcus 提问** 询问剔除Alaris和特殊项目后,基础业务的增长情况 [46] **Tom Polen 和 Chris DelOrefice 回答** - 医疗和介入业务以及专注于医疗服务提供商的生命科学业务保持强劲增长,抵消了制药系统和生命科学研究业务的短期波动 [47][48][49][50][51][52] 问题3 **Vijay Kumar 提问** 询问Alaris在2024财年第四季度的收入规模 [57] **Tom Polen 和 Chris DelOrefice 回答** - 2024财年Alaris收入预计至少3.5亿美元,接近公司之前披露的400万美元的历史水平 [59][60][61]

For the quarter ended March 2024, Becton Dickinson (BDX) reported revenue of $5.05 billion, up 4.7% over the same period last year. EPS came in at $3.17, compared to $2.86 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $5.03 billion, representing a surprise of +0.30%. The company delivered an EPS surprise of +7.09%, with the consensus EPS estimate being $2.96. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

Becton, Dickinson and Company (BDX) , popularly known as BD, delivered adjusted earnings per share (EPS) of $3.17 in the second quarter of fiscal 2024, up 10.8% year over year. The figure topped the Zacks Consensus Estimate by 7.1%. The adjustments include expenses related to purchase accounting adjustments and integration costs, among others. GAAP EPS for the quarter was $1.85, reflecting an improvement of 20.9% from the year-earlier figure. Revenues in Detail BD registered revenues of $5.05 billion in the ...